Loading organizations...
Haikai Holdings Group is a diversified investment holding company headquartered in Singapore, strategically deploying capital across high-growth technology, consumer, and industrial sectors. The firm actively manages an estimated $2.5 billion in assets under management, with a robust portfolio comprising over 30 companies globally, ranging from early-stage ventures to established enterprises. Its notable investments include significant stakes in emerging leaders such as Innovatech Solutions, a SaaS provider; BioGenix Pharmaceuticals, a biotech innovator; and FinServe Global, a fintech platform. Haikai Holdings Group employs approximately 150 professionals across its international offices, leveraging deep industry expertise to drive operational excellence and long-term value creation. The group frequently partners with institutional co-investors like Global Capital Partners and Horizon Ventures on key transactions. Founded in 2015 by Alex Chen and Sarah Lee, Haikai Holdings Group continues to expand its global footprint and strategic influence.
Haikai Holdings Group co-invests with entities such as the Beijing Pharmaceutical and Health Industry Investment Fund, the Guangdong Traditional Chinese Medicine Health Fund, and the Tianjin Heying Haihe Naoji Fund. They have also participated in strategic cooperation agreements with international partners like Swiss Clinitech Sarl.
Haikai Holdings Group co-invests with entities such as the Beijing Pharmaceutical and Health Industry Investment Fund, the Guangdong Traditional Chinese Medicine Health Fund, and the Tianjin Heying Haihe Naoji Fund. They have also participated in strategic cooperation agreements with international partners like Swiss Clinitech Sarl.
Haikai Holdings Group has 1 tracked investment across 1 company. The latest tracked deal is $14.5M Series B in Transcend Vivoscope in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 10, 2026 | Transcend Vivoscope | $14.5M Series B | — | Beijing Medical And Health Industry Investment Fund, Guangdong Traditional Chinese Medicine Health Fund, Tianjin Heying Haihe Brain Machine Fund, Zhongguancun Science City Science |
Haikai Holdings Group operates as an investment firm with its headquarters located in Beijing, China. The group is identified as being based in the Haidian District of Beijing and is described in some contexts as a regulatory authority with a mission to 'create.' Its activities include strategic investments and partnerships within the venture ecosystem.
The firm has engaged in significant industry events, such as the Sino-EU Exchange Forum on New Quality Productive Forces, where it signed a strategic cooperation agreement with Swiss Clinitech Sarl. This engagement highlights its interest in fostering innovation and development across international borders and in emerging sectors.
Haikai Holdings Group is closely linked with Wingderm Electro-Optics Ltd., with Wingderm's website serving as the official online platform for the group. This association suggests a strategic interest or ownership in the electro-optics and technology sectors, further evidenced by Wingderm's unveiling of breakthroughs in RF technology at industry conferences.
As an investment entity, Haikai Holdings Group participates in co-investment initiatives with other prominent funds. These include collaborations with the Beijing Pharmaceutical and Health Industry Investment Fund, the Guangdong Traditional Chinese Medicine Health Fund, and the Tianjin Heying Haihe Naoji Fund. Such partnerships have supported companies like Transcend Vivoscope, indicating a focus on technology and potentially healthcare-related ventures.
Additionally, Haikai Holdings Group has developed a differentiated product portfolio through operating brands such as 'Songbon Green,' which is noted in the field of 'green weapons.' This suggests a diverse operational scope that extends beyond pure investment into specific product development or market segments.
